← Leaderboards
Manish Bais
Boston University Medical Campus
$3,000,764
Attributed
$3,000,764
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $659.1K · FY2015–25$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,000,764 · 3
By mechanism
R01$2,301,464 · 1
R21$453,750 · 1
R03$245,550 · 1
Top collaborators
No co-investigators on record.
Most similar at Boston University Medical Campus
Same institution · by research overlap
- Robert A Lafyatis$10,905,922
- Herbert Marcus Kagan$3,603,329
- Stefano Monti$4,870,283
- Sayon Roy$8,593,373
- Paul F Pilch$12,079,735
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelLeadAttenuatedPathway InteractionsPublishingCellsFutureMouth Squamous Cell CarcinomaEpidermal Growth Factor ReceptorOral CavityEnzymesEnvironmentMalignant NeoplasmsKeratinAttenuationChromatinEffective TherapyIn VivoGeneticCessation Of LifeBiologyEpigenetic ProcessKdm1a GeneMalignant Mouth Neoplasm
Grant awards (10)
Mechanism of LSD1 Function and Its Therapeutic Application for Progressive Oral Malignancy$461,416
R01 · FY2025 · DE · contact PI
Mechanism of LSD1 Function and Its Therapeutic Application for Progressive Oral Malignancy$523,816
R01 · FY2024 · DE · contact PI
Mechanism of LSD1 Function and Its Therapeutic Application for Progressive Oral Malignancy$72,474
R01 · FY2024 · DE · contact PI
Mechanism of LSD1 Function and Its Therapeutic Application for Progressive Oral Malignancy$14,491
R01 · FY2024 · DE · contact PI
Mechanism of LSD1 Function and Its Therapeutic Application for Progressive Oral Malignancy$659,051
R01 · FY2023 · DE · contact PI
Mechanism of LSD1 Function and Its Therapeutic Application for Progressive Oral Malignancy$570,216
R01 · FY2022 · DE · contact PI
Epigenetic targeting of LSD1 for OSCC Therapy$206,250
R21 · FY2019 · DE · contact PI
Epigenetic targeting of LSD1 for OSCC Therapy$247,500
R21 · FY2018 · DE · contact PI
LOXL2 in Temporomandibular Joint Osteoarthritis$122,775
R03 · FY2016 · DE · contact PI
LOXL2 in Temporomandibular Joint Osteoarthritis$122,775
R03 · FY2015 · DE · contact PI